Loading…
Scynexis Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -89.0% over 5Y.
today you would have $103.54▼ -89.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.06 | $9.68 | $17.84 | $12.48 | |
| P/E | — | — | — | 1.6x | — |
| P/S | 5.7x | 1.3x | 12.3x | 0.6x | 10.0x |
| P/B | 1.0x | 0.6x | 0.8x | 1.1x | 15.8x |
| EPS | -$1.36 | -$3.52 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XTNTXtant Medical Holdings, Inc. | $0.38 | — | 1.3x | — | -25.16% | $53.87M |
| COCHEnvoy Medical, Inc. | $0.69 | — | 14.4x | — | — | $53.27M |
| BTMDbiote Corp. | $1.57 | 11.2x | — | — | — | $53.22M |
| NTRBNutriBand Inc. | $4.46 |
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Company description provided by Yahoo Finance.
| $11.12 |
| -$11.76 |
| Profit margin | -305.04% | -41.79% | -568.29% | 47.84% | -1233.73% |
| ROE | -28.04% | -17.44% | -38.65% | 91.88% | -1942.75% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 9.0x |
| — |
| -145.72% |
| $54.22M |
| HRTXHeron Therapeutics Inc | $0.29 | — | 9.4x | — | — | $55.25M |
| ELOXEloxx Pharmaceuticals, Inc. | $15.07 | 4.7x | 1.3x | — | — | $51.79M |